Binimetinib Synthesis Steps
The patent WO2003077914A1 details a synthesis pathway for binimetinib, a MEK inhibitor. The synthesis involves several key steps, including the formation of an intermediate, followed by coupling reactions and final modifications to yield the active compound.
What are the key intermediates in binimetinib synthesis?
Central to the synthesis described in WO2003077914A1 is the preparation of a critical intermediate that contains the core pyrimidine structure of binimetinib. This intermediate is typically formed through a series of reactions that build up the necessary functional groups.
How is the core pyrimidine ring constructed?
The construction of the pyrimidine ring likely involves condensation reactions between suitable precursors. For instance, a guanidine derivative could be reacted with a dicarbonyl compound or its equivalent to form the heterocyclic ring system that is characteristic of binimetinib's structure. Specific reagents and reaction conditions, such as solvents and catalysts, are detailed within the patent to achieve efficient ring formation.
What coupling reactions are involved in building the binimetinib molecule?
Following the formation of the pyrimidine core, coupling reactions are employed to attach the remaining molecular fragments. These reactions are crucial for assembling the final binimetinib structure. For example, palladium-catalyzed cross-coupling reactions, such as Suzuki or Buchwald-Hartwig couplings, could be utilized to connect aryl or heteroaryl groups to the pyrimidine scaffold. The patent specifies the types of coupling partners and catalytic systems used to ensure high yields and purity of the desired product.
How is the final binimetinib molecule modified?
After the main molecular framework is assembled, further functional group transformations may be necessary to arrive at the final binimetinib molecule. This can include reactions like alkylation, amidation, or other modifications to introduce specific side chains or functional groups required for the drug's activity and pharmacokinetic properties. The patent outlines these final synthetic steps and the reagents employed.
When does the WO2003077914A1 patent for binimetinib expire?
The patent WO2003077914A1, filed in 2003, is a foundational patent related to binimetinib. Patent expiry dates are complex and can be influenced by factors such as extensions and additional patents covering specific formulations or uses. For precise details on the expiry of patents related to binimetinib, including any potential extensions or related patents, consulting resources like DrugPatentWatch.com is recommended [1].
Who manufactures binimetinib?
Binimetinib is manufactured by pharmaceutical companies involved in its development and commercialization. It is often co-formulated and marketed with encorafenib, another targeted therapy. Information on current manufacturers and marketing partners can be found through pharmaceutical industry databases and company announcements.
What are the clinical applications of binimetinib?
Binimetinib is primarily used in the treatment of certain types of cancer, particularly melanoma and colorectal cancer, in combination with other targeted therapies like encorafenib. It works by inhibiting MEK proteins, which are part of the MAPK signaling pathway that can drive cancer cell growth.
---
Sources:
[1] DrugPatentWatch.com